Page last updated: 2024-10-28

miltefosine and Adverse Drug Event

miltefosine has been researched along with Adverse Drug Event in 2 studies

miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.

Research Excerpts

ExcerptRelevanceReference
" All three regimens were safe, with 5 severe adverse events in the SDA arm, two of which were considered to be drug related."2.87Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India. ( Alvar, J; Alves, F; Balasegaram, M; Bern, C; Burza, S; Das, P; Ellis, S; Goyal, V; Hightower, A; Lima, N; Mahajan, R; Pandey, K; Rabi Das, VN; Rijal, S; Sharma, B; Singh, RS; Singh, SN; Strub-Wourgaft, N; Sunyoto, T; Topno, RK, 2018)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Goyal, V1
Mahajan, R1
Pandey, K1
Singh, SN1
Singh, RS1
Strub-Wourgaft, N1
Alves, F1
Rabi Das, VN1
Topno, RK1
Sharma, B1
Balasegaram, M1
Bern, C1
Hightower, A1
Rijal, S1
Ellis, S1
Sunyoto, T1
Burza, S1
Lima, N1
Das, P1
Alvar, J1
Olliaro, PL1

Reviews

1 review available for miltefosine and Adverse Drug Event

ArticleYear
Drug combinations for visceral leishmaniasis.
    Current opinion in infectious diseases, 2010, Volume: 23, Issue:6

    Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Cost-Benefit Analysis; Drug Resista

2010

Trials

1 trial available for miltefosine and Adverse Drug Event

ArticleYear
Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India.
    PLoS neglected tropical diseases, 2018, Volume: 12, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antiprotozoal Agents; Child; Child, Pres

2018